These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24379140)

  • 1. MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis.
    Chen QW; Chen H; Cheng JS; Meng ZQ
    Tumour Biol; 2014 May; 35(5):4147-51. PubMed ID: 24379140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis.
    Wang LH; Wang X; Xu WT; Hu YL
    Tumour Biol; 2014 Apr; 35(4):3167-70. PubMed ID: 24293392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis.
    Liu GY; Jiang DK; Shen SQ; Yu L
    Arch Med Res; 2011 Feb; 42(2):149-55. PubMed ID: 21565629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis.
    Duan X; Li J
    Medicine (Baltimore); 2017 Sep; 96(36):e7856. PubMed ID: 28885338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
    Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
    Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
    Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
    PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population.
    Wang X; Zhang X; Qiu B; Tang Y; Sun H; Ji H; Liu Y; Shi L; Song G; Yang Y
    Liver Int; 2012 Aug; 32(7):1172-8. PubMed ID: 22413855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: a meta-analysis.
    Wang HG; Wu QY; Zhou H; Peng XS; Shi MJ; Li JM; Zhou YF
    Asian Pac J Cancer Prev; 2014; 15(13):5277-81. PubMed ID: 25040988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
    Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
    Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis.
    Liu J; Zheng Y; Lei D; Liu D; Xu F; Jin T; Cao X; Zhao X; Yu X; Pan X
    Asian Pac J Cancer Prev; 2011; 12(8):1899-903. PubMed ID: 22292622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis.
    Liu Y; Kuang S; Zheng J; Zheng J; Jin H; Chen S; Jian Z
    Tumour Biol; 2014 Feb; 35(2):961-5. PubMed ID: 24061636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive evaluation of single nucleotide polymorphisms associated with hepatocellular carcinoma risk in Asian populations: A systematic review and network meta-analysis.
    Zhang C; Ye Z; Zhang Z; Zheng J; Tang Y; Hou E; Huang Z; Meng L
    Gene; 2020 Apr; 735():144365. PubMed ID: 31935498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies.
    Li JF; Zheng EQ; Xie M
    Gene; 2019 Feb; 685():143-148. PubMed ID: 30403964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.
    Zhao E; Cui D; Yuan L; Lu W
    Mol Biol Rep; 2012 Apr; 39(4):3471-7. PubMed ID: 21725850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
    Dharel N; Kato N; Muroyama R; Moriyama M; Shao RX; Kawabe T; Omata M
    Clin Cancer Res; 2006 Aug; 12(16):4867-71. PubMed ID: 16914573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis.
    Ma HB; Huang T; Han F; Chen WY
    Asian Pac J Cancer Prev; 2012; 13(6):2841-6. PubMed ID: 22938470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.
    Ezzikouri S; Essaid El Feydi A; Afifi R; Benazzouz M; Hassar M; Pineau P; Benjelloun S
    Int J Biol Markers; 2011; 26(4):229-33. PubMed ID: 22180176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of MDM2 single nucleotide polymorphism on oral squamous cell carcinoma risk.
    Xie JL; Yang JL; Liu DS; Xie YG; Ji P
    Cell Biochem Biophys; 2015 Mar; 71(2):993-8. PubMed ID: 25323564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.